Seres Therapeutics DEFA14A: Executive Compensation Details
Ticker: MCRB · Form: DEFA14A · Filed: Apr 4, 2025 · CIK: 1609809
| Field | Detail |
|---|---|
| Company | Seres Therapeutics, Inc. (MCRB) |
| Form Type | DEFA14A |
| Filed Date | Apr 4, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, sec-filing
TL;DR
Seres Therapeutics dropped its DEFA14A, showing exec pay details for 2024. Focus on stock/option awards and pension adjustments.
AI Summary
Seres Therapeutics, Inc. filed a DEFA14A on April 4, 2025, detailing executive compensation and related matters for the fiscal year ending December 31, 2024. The filing includes information on stock awards, option awards, and pension adjustments for both PEO (Principal Executive Officer) and Non-PEO NEO (Named Executive Officers).
Why It Matters
This filing provides transparency into how Seres Therapeutics compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: low — This is a routine filing providing details on executive compensation and does not inherently present new financial risks.
Key Players & Entities
- Seres Therapeutics, Inc. (company) — Filer of the DEFA14A
- 20250404 (date) — Filing date of the DEFA14A
- 2024-12-31 (date) — Fiscal year end for which compensation is reported
- 200 SIDNEY STREET, CAMBRIDGE, MA 02139 (address) — Business and mailing address of Seres Therapeutics
FAQ
What is the primary purpose of a DEFA14A filing?
A DEFA14A filing, also known as a definitive proxy statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors, executive compensation, and other proposals.
What fiscal year does this DEFA14A filing primarily cover?
This DEFA14A filing primarily covers the fiscal year ending December 31, 2024, with some comparative data for prior years like 2022 and 2023.
What specific types of compensation are detailed in this filing for executives?
The filing details compensation related to stock awards, option awards, and pension adjustments for both PEO (Principal Executive Officer) and Non-PEO NEO (Named Executive Officers).
What is the standard industrial classification for Seres Therapeutics, Inc.?
The standard industrial classification for Seres Therapeutics, Inc. is Pharmaceutical Preparations [2834].
When was Seres Therapeutics, Inc. formerly known as Seres Health, Inc.?
The company formerly known as Seres Health, Inc. changed its name to Seres Therapeutics, Inc. on June 3, 2014.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 4, 2025 regarding Seres Therapeutics, Inc. (MCRB).